JP2019526632A - 固形腫瘍の治療のための投薬レジメン - Google Patents

固形腫瘍の治療のための投薬レジメン Download PDF

Info

Publication number
JP2019526632A
JP2019526632A JP2019531873A JP2019531873A JP2019526632A JP 2019526632 A JP2019526632 A JP 2019526632A JP 2019531873 A JP2019531873 A JP 2019531873A JP 2019531873 A JP2019531873 A JP 2019531873A JP 2019526632 A JP2019526632 A JP 2019526632A
Authority
JP
Japan
Prior art keywords
dose
cancer
oxo
administered
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019531873A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526632A5 (enExample
Inventor
ベンハジ，カリム，アドナン
ユエン，ユニス，ソク，ムン
Original Assignee
イーライ リリー アンド カンパニー
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー, イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2019526632A publication Critical patent/JP2019526632A/ja
Publication of JP2019526632A5 publication Critical patent/JP2019526632A5/ja
Priority to JP2022209634A priority Critical patent/JP2023052108A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019531873A 2016-08-31 2017-08-24 固形腫瘍の治療のための投薬レジメン Pending JP2019526632A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022209634A JP2023052108A (ja) 2016-08-31 2022-12-27 固形腫瘍の治療のための投薬レジメン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662381911P 2016-08-31 2016-08-31
US62/381,911 2016-08-31
PCT/US2017/048308 WO2018044662A1 (en) 2016-08-31 2017-08-24 Dosage regimen for treatment of solid tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022209634A Division JP2023052108A (ja) 2016-08-31 2022-12-27 固形腫瘍の治療のための投薬レジメン

Publications (2)

Publication Number Publication Date
JP2019526632A true JP2019526632A (ja) 2019-09-19
JP2019526632A5 JP2019526632A5 (enExample) 2020-10-01

Family

ID=59772787

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019531873A Pending JP2019526632A (ja) 2016-08-31 2017-08-24 固形腫瘍の治療のための投薬レジメン
JP2022209634A Pending JP2023052108A (ja) 2016-08-31 2022-12-27 固形腫瘍の治療のための投薬レジメン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022209634A Pending JP2023052108A (ja) 2016-08-31 2022-12-27 固形腫瘍の治療のための投薬レジメン

Country Status (14)

Country Link
US (1) US20190209581A1 (enExample)
EP (1) EP3506905B1 (enExample)
JP (2) JP2019526632A (enExample)
KR (1) KR102512899B1 (enExample)
CN (2) CN109562114A (enExample)
AU (1) AU2017321011B2 (enExample)
BR (1) BR112019002461A2 (enExample)
CA (1) CA3035616A1 (enExample)
ES (1) ES2977556T3 (enExample)
IL (2) IL305136A (enExample)
MA (1) MA46086A (enExample)
MX (1) MX387397B (enExample)
SG (2) SG10202107832UA (enExample)
WO (1) WO2018044662A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
RU2754452C2 (ru) 2016-04-12 2021-09-02 Эли Лилли Энд Компани Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака
ES2881801T3 (es) 2016-04-12 2021-11-30 Lilly Co Eli Terapia de combinación con inhibidores de Notch y CDK4/6 para su uso en el tratamiento de cáncer de pulmón
KR102463617B1 (ko) 2016-05-20 2022-11-03 일라이 릴리 앤드 캄파니 Notch 및 PD-1 또는 PD-L1 억제제를 이용한 조합 요법
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
SG11201907580SA (en) 2017-02-17 2019-09-27 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
AU2018359907A1 (en) 2017-11-06 2020-05-07 Fred Hutchinson Cancer Center Combination of a cell therapy and a gamma secretase inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112249A1 (en) * 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
JP2011503073A (ja) * 2007-11-13 2011-01-27 メリテイジ ファーマ，インク． コルチコステロイド組成物
JP2014527042A (ja) * 2011-07-27 2014-10-09 イーライ リリー アンド カンパニー ノッチ経路シグナリングインヒビター化合物
WO2016007775A1 (en) * 2014-07-11 2016-01-14 Genentech, Inc. Notch pathway inhibition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US46206A (en) 1865-02-07 Improved vessel for holding petroleum
TWI609687B (zh) * 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112249A1 (en) * 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
JP2011503073A (ja) * 2007-11-13 2011-01-27 メリテイジ ファーマ，インク． コルチコステロイド組成物
JP2014527042A (ja) * 2011-07-27 2014-10-09 イーライ リリー アンド カンパニー ノッチ経路シグナリングインヒビター化合物
WO2016007775A1 (en) * 2014-07-11 2016-01-14 Genentech, Inc. Notch pathway inhibition

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BENDER, MARK H. ET AL.: "Abstract 1131: Novel inhibitor of Notch signaling for the treatment of cancer.", CANCER RESEARCH, vol. 73 (8), JPN6021016158, 2013, pages 1131, ISSN: 0004710918 *
EUNICE YUEN: "Population pharmacokinetics and pharmacodynamics for an oral notch inhibitor, LY3039478, in the firs", CANCER RESEARCH, vol. V76 N14 SUPPL, JPN5019008214, July 2016 (2016-07-01), pages 1 - 4, ISSN: 0004710917 *
MASSARD, CHRISTOPHE ET AL.: "First-in-human study of LY3039478, a Notch signaling inhibitor in advanced or metastatic cancer.", JOURNAL OF CLINICAL ONCOLOGY, vol. 33 (15 suppl), JPN6021016157, 2015, pages 2533 - 2533, ISSN: 0005008409 *
臨床薬理, vol. 41巻，4号, JPN6022006024, 2010, pages 155 - 158, ISSN: 0005008410 *
鹿児島市医報, vol. 第53巻，第10号, JPN6022006023, 2014, pages 18 - 19, ISSN: 0005008411 *

Also Published As

Publication number Publication date
JP2023052108A (ja) 2023-04-11
MX387397B (es) 2025-03-18
IL264924B1 (en) 2023-09-01
MA46086A (fr) 2019-07-10
IL305136A (en) 2023-10-01
AU2017321011A1 (en) 2019-02-21
US20190209581A1 (en) 2019-07-11
CN109562114A (zh) 2019-04-02
WO2018044662A1 (en) 2018-03-08
CA3035616A1 (en) 2018-03-08
ES2977556T3 (es) 2024-08-26
BR112019002461A2 (pt) 2019-05-14
EP3506905B1 (en) 2024-03-20
IL264924A (enExample) 2019-04-30
AU2017321011B2 (en) 2023-08-03
EP3506905A1 (en) 2019-07-10
SG11201901325UA (en) 2019-03-28
KR102512899B1 (ko) 2023-03-23
IL264924B2 (en) 2024-01-01
KR20190042591A (ko) 2019-04-24
MX2019002066A (es) 2019-06-03
CN116473978A (zh) 2023-07-25
SG10202107832UA (en) 2021-09-29

Similar Documents

Publication Publication Date Title
JP2019526632A (ja) 固形腫瘍の治療のための投薬レジメン
Lee et al. NTRK and RET fusion–directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake
Dolly et al. Phase I study of apitolisib (GDC-0980), dual phosphatidylinositol-3-kinase and mammalian target of rapamycin kinase inhibitor, in patients with advanced solid tumors
Hall et al. A phase I study of pegylated arginine deiminase (pegargiminase), cisplatin, and pemetrexed in argininosuccinate synthetase 1-deficient recurrent high-grade glioma
US8637554B2 (en) Methods for treating thyroid cancer
US10183019B2 (en) Treatment of cancer with dihydropyrazino-pyrazines
CN103327976A (zh) 基于缺氧状态预选受试者以用于治疗性治疗
US20150253330A1 (en) Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitor based on hypoxic status
Pantel et al. [18F] FluorThanatrace ([18F] FTT) PET imaging of PARP-inhibitor drug-target engagement as a biomarker of response in ovarian cancer, a pilot study
US20130237546A1 (en) Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma
JP2023508996A (ja) Ｃｄｋ１２／１３阻害剤を用いる癌の処置
CA3039405A1 (en) Targeted treatment of mature t-cell lymphoma
JP2013545759A (ja) 低酸素状態に基づくエレスクロモールによる治療に適した被験体の事前選択
US20200397796A1 (en) Methods of treatment of cancer comprising chk1 inhibitors
HK40009858A (en) Dosage regimen for treatment of solid tumors
HK40009858B (en) Dosage regimen for treatment of solid tumors
JP2016526032A (ja) ポジション（ｐｏｓｉｔｉｏｎ）放射断層撮影（ｐｅｔ）スキャンでリファキシミンを使用する方法
NZ791442A (en) Dosage regimen for treatment of solid tumors
JP2022532597A (ja) Ｃｈｋ１阻害剤を使用してがんを治療する方法
Wada et al. The impact of alkalizing the acidic tumor microenvironment to improve efficacy of cancer treatment
WO2024186693A1 (en) Methods of treating cancer with a ras mutation
WO2025199440A1 (en) Methods of treating liposarcoma using a pyrazole compound
HK40081065A (en) Treatment of cancer with cdk12/13 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200821

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220804

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221227

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221227

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230117

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230127

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230131

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230310

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230314